Inhibitory effects of some Schiff bases and metal complexes on xanthine oxidase

Gout, cancer, diabetes, and metabolic syndrome are all linked to xanthine oxidase deficiency. Schiff Bases and Metal Complexes, a bioactive substance, and its derivates were tested for their ability to inhibit the enzyme xanthine oxidase in the present study. The objective is to create bioactives with antioxidant potential from Schiff Bases and Metal Complexes. Metal complexes, Schiff bases, hydrazines and natural acids were all employed to produce ester bonds using molecular docking techniques. The compounds' antioxidant and xanthine oxidase inhibitory activities were evaluated. 4-Metoksi S1 derivatives demonstrated a competitive inhibition of XO ability with IC50 value of 6,601 M and 4-Metoksi S1 was identified as the most active derivative. In the binding site of XO, the new 4-metoksi S1 derivatives bind to amino acid residues Leu257, Glu263, Thr262, Gly260, Ser347, Alkyl and Pi-Alkyl (Lys256, Ile353, Val259, Leu305, Ala346, Phe337). Testing for antioxidant capability of all compounds revealed that they were all very effective. Hybridization of Schiff Bases and Metal Complexes 4-metoksi S1 might lead to more potent xanthine oxidase inhibitors via molecular docking.